Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC) -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (449)	2/23/2005 9:11:53 PM
From: quidditch	Read Replies (1) \| Respond to of 946

Peter, on that score--top line data--could you review briefly the primary endpoint in terms of survival benefit? I believe benefit was to be measured vs. taxol, as the control arm. What was SPA's primary endpoint--was it in terms of weeks or months of benefit? And given Bianco's event analysis, the talk on the thread was that the trial had continued--i.e., "events" had been delayed--longer than was anticipated (by whom?), leading to speculation that the endpoint might well have been met. How much credence is to be given to that "event" analysis and the prolongation of the trial, if in fact that is what occurred? tia, quid

To: Biomaven who wrote (449)	2/24/2005 1:57:34 AM
From: tuck	Read Replies (2) \| Respond to of 946

Of course, it's old news. But the issue wasn't quite resolved to my satisfaction. Miljenko made his statement and backed it up to a certain degree in a subsequent post to Rudy, then you and I presented counterarguments, but Miljenko did not reply to those. Miljenko has saved my bacon at least once with such a warning, and he has demonstrated numerous times that he knows his stuff way better than I do, so I pay attention when he says such things. I was sitting on a near double and sold thirty percent or so of my holdings, such that I am playing with house money. So no disaster, but definite disappointment if he turns out to be right. At this point, I don't think he is, but . . . Either way, when the buzz dies down, I may well buy more for the Pixantrone program . . . Wonder if there was anything compelling earlier in the pipe that they got in that munch. I haven't thought to look. Cheers, Tuck